Corporate
2017.08.28
Lumosa partners with Camargo for LT1001
Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain(R) in the US
Corporate
2017.06.20
USFDA approved the phase 1 trial for LT3001
Lumosa Therapeutics Co., Ltd., (TPEx: 6535, hereinafter 'Lumosa') is pleased to announce that its lead drug candidate for acute ischemic stroke, LT3001, has received approval from the US FDA to begin Phase I clinical trials. The first clinical trial is a double-blinded dose escalating study in healthy volunteers and expected to be completed in the first half of 2018.
Corporate
2017.03.06
Lumosa's LT1001 approved by Taiwan FDA
Lumosa Therapeutics Co., Ltd. (Lumosa, 6535.TWO) announced the approval of LT1001, a long-acting analgesic injection (product name: Naldebain®) by Taiwan Food and Drug Administration (TFDA) today (March 6, 2017). Naldebain®, soon to be launched in Taiwan, is 100% "made in Taiwan"; from concept through product development, clinical trials, and dossier compilation.
Corporate
2017.03.01
Lumosa scientist spoke at 2017 International Stroke Conference
Lumosa Therapeutics Co., Ltd. (Lumosa, 6535.TWO) announced the preclinical study results of its drug candidate for the treatment of acute ischemic stroke at the International Stroke Conference 2017 (ISC).
Corporate
2016.12.12
Naldebain® draws attention at Taiwan Society of Colon and Rectal Surgeions
Dr. Chien-Yuh Yeh was invited to report the phase 3 trial results of Naldebain® (dinalbuphine sebacate) I.M. Injection (also called LT1001) at the Annual Meeting of Taiwanese Society of Colon and Rectal Surgeons held in Kaohsiung, Taiwan on December 10, 2016. The Society celebrated its 30th anniversary since inception. Speaker Dr. Yeh is a practicing surgeon at Chang Gung Memorial Hospital and one of the lead investigators of this phase 3 trial. The title of his presentation was “A Phase III Trial of a Novel Long Acting Painkiller,” which highlighted the unique safety and long-lasting efficacy profile of the product.
Corporate
2016.11.14
Lumosa presents LT3001 at the stroke forum
Taiwan Stroke Society held its 2016 Annual Meeting and the inaugural “Asia Pacific Stroke Forum" (hereafter referred to as “the Forum”) on November 12 and 13 in The Grand Hotel, Taipei. Stroke specialists and key opinion leaders all over the world were invited to discuss the newest stroke treatment methods. Dr. Sheng-Wen Yeh of Lumosa Therapeutics (Lumosa, TPEx:6535) was invited to give an orally presentation on the findings in a recent non-primate study of LT3001, a novel chemical entity under development by Lumosa for the treatment of acute ischemic stroke.